Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 20

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 20
---
mine, which is the dominant metabolite. Abundant scientific literature has confirmed the antiviral, metabolic, and immunosuppressive properties of castanospermine alkaloids. The Company currently has at least 8.8 kgs of castanospermine in inventory which will be used for additional proof of concept studies.

| 30 | Sorbera et al, Drugs of the Future 2005; 30:545-552. |

| 31 | Low et. al., Lancet ID 2014; 14:706-715. |

| 32 | Watanabe et al, Antiviral Research 2016; 10:e19. |

<div align='center'>6</div>

Strategy

Our general strategy to achieve profitability
and grow shareholder value has three facets: (i) increase sales of Arakoda; (ii) conduct clinical trials to expand the number of patients
who can use Tafenoquine for new indications in the future; and (iii) reposition small molecule therapeutics with good clinical safety
profiles for new indications.

Expansion of U.S. Arakoda Sales

. In February 2024, we hired
Kristen Landon to lead our commercial efforts to reintroduce Arakoda for malaria prevention and conduct new product planning initiatives
in tick-borne disease for babesiosis. We spent the first quarter of 2024 analyzing the current landscape in the malaria prevention market,
conducting primary market research among providers and consumers, and assessing agency partners for a virtual/digital marketing pilot
program. Additionally, we kicked off a market assessment on the babesiosis space including desk top research and qualitative interviews
with Key Opinion Leaders in the Infectious Disease and Lyme Community, a quantitative market survey of 300 prescribing physicians, a survey
of 6,000 U.S. consumers, and an administrative claims study. Thee outputs of these surveys together suggest a substantial market opportunity.

. A malaria demand study was conducted to assess the attractiveness and acceptability of
the Arakoda product profile and current pricing among health care providers and consumers. The product profile was well received among
both stakeholders; however, price sensitivity on out-of-pocket costs was noted among both groups. Generic atovaquone-proguanil, our primary
competitor is substantially cheaper than Arakoda for the average trip length (three weeks) and has superior formulary positioning (Tier
1 vs. Tier 3). However, generic-atovaquone proguan